Supplemental New Drug Application for Risperdal Consta Submitted to … - Phramalive.com
CAMBRIDGE, Mass.–(BUSINESS WIRE)–July 24, 2008–Alkermes, Inc. (NASDAQ: ALKS) today announced that its partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), submitted a supplemental New Drug Application (sNDA) for …